Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis
Yang, Bin
Yang, Bin
Abstract
The progression of renal fibrosis to end-stage renal disease (ESRD) is significantly influenced by transforming growth factor-beta (TGF-beta) signal pathway. This study aimed to develop nanoparticles (PMVs@PLGA complexes) with platelet membrane camouflage, which can transport interfering RNA to target and regulate the TGF-β1 pathway in damaged renal tissues. The aim is to reduce the severity of acute kidney injury and to reduce fibrosis in chronic kidney disease. Hence, we formulated PMVs@TGF-β1-siRNA NP complexes and employed them for both in vitro and in vivo therapy. From the experimental findings we know that the PMVs@siRNA NPs could effectively target the kidneys in unilateral ureteral obstruction (UUO) mice and ischemia/reperfusion injury (I/R) mice. In animal models of treatment, PMVs@siRNA NP complexes effectively decreased the expression of TGF-β1 and mitigated inflammation and fibrosis in the kidneys by blocking the TGF-β1/Smad3 pathway. Therefore, these PMVs@siRNA NP complexes can serve as a promising biological delivery system for treating kidney diseases.
MIDER Authors
Citations
Altmetric:
Date
2024-06-25
Type
Article
Subject
Chronic kidney disease, Platelet membrane-camouflaging nanoparticles, Renal fibrosis, TGF-β1 siRNA, Targeted therapy
Collections
Citation
Fei, S., Ma, Y., Zhou, B., Chen, X., Zhang, Y., Yue, K., Li, Q., Gui, Y., Xiang, T., Liu, J., Yang, B., Wang, L., & Huang, X. (2024). Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis. International journal of pharmaceutics, 659, 124261. https://doi.org/10.1016/j.ijpharm.2024.124261